# Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study

> **NCT06058234** · — · RECRUITING · sponsor: **Centers for Medicare and Medicaid Services/ Coverage and Analysis Group** · enrollment: 8680 (estimated)

## Conditions studied

- Mild Alzheimer's Disease
- Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease

## Interventions

- **DRUG:** Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease

## Key facts

- **NCT ID:** NCT06058234
- **Lead sponsor:** Centers for Medicare and Medicaid Services/ Coverage and Analysis Group
- **Sponsor class:** FED
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-06
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 8680 (ESTIMATED)
- **Last updated:** 2023-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06058234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06058234, "Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06058234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*